I-11 Christian Bartels Relation of FEV1 to COPD Patient Outcomes: A patient level pooled analysis of COPD clinical trials Wednesday 10:45-12:15 |
I-16 Jan Berkhout Systems pharmacology modeling describing osteoporotic disease progression in a population of postmenopausal women receiving placebo or alendronate Wednesday 10:45-12:15 |
I-26 Boram Ohk Population pharmacokinetics of Fimasartan Wednesday 10:45-12:15 |
I-29 Rolien Bosch A mechanism-based model is able to simultaneously explain the effect of rhLCAT and HDL mimetics on biomarkers of reverse cholesterol transport Wednesday 10:45-12:15 |
I-30 Marion Bouillon-Pichault Longitudinal Model-Based Meta-Analysis in Type 2 Diabetes: Assessment of link between fasting plasma glucose and Hba1c. Wednesday 10:45-12:15 |
I-31 Karl Brendel How to consider microdosing data in a population PK analysis? Wednesday 10:45-12:15 |
I-41 Massimo Cella Use of a TMDD model in the translational development of a BDNF-neutralizing monoclonal antibody Wednesday 10:45-12:15 |
I-42 Dong Woo Chae Mechanistic Modeling of Telmisartan Blood Pressure Lowering Effect in Human Wednesday 10:45-12:15 |
I-48 Pierre Chelle Assessment of Endogenous Thrombin Potential predictive potential of Thrombin Generation mechanistic models with Hemophilic A patients Wednesday 10:45-12:15 |
I-59 Francois Combes Population Pharmacodynamic Modeling and Simulation of Anti-Obesity Clinical Trials to Explore Longitudinal Weight Loss Wednesday 10:45-12:15 |
I-60 Emmanuelle Comets Joint modelling of iron and hepcidin during the menstrual cycle Wednesday 10:45-12:15 |
I-72 Willem de Winter A dynamic population PK/PD model to assess the effect of once daily versus twice daily dosing regimens on the relationship between canagliflozin plasma exposure and HbA1c response Wednesday 10:45-12:15 |
I-73 Wilbert de Witte What is the influence of diffusion-limited binding on in vivo target occupancy profiles? Wednesday 10:45-12:15 |
I-77 Cheikh Diack An empirical drug-disease model to characterize the effect of Ranibizumab on disease progression in wet AMD patients Wednesday 10:45-12:15 |
II-07 Marina Senek Population pharmacokinetic modelling of Levodopa/Carbidopa Microtablets versus standard formulations of Levodopa/Benserazide and Levodopa/Carbidopa Wednesday 15:15-16:40 |
II-08 Kok-Yong Seng Evaluating Ethnicity Differences in the Effect of Ritonavir, Ketoconazole and Rifampicin on Cytochrome P450 3A Induction and Inhibition in the Asian and Western Populations Wednesday 15:15-16:40 |
II-09 Seonghae Yoon Population pharmacokinetics/pharmacodynamics modeling of uric acid formation after xanthine oxidase inhibitor administrations Wednesday 15:15-16:40 |
II-18 Elena Soto Model informed drug discovery and development of novel treatments for hyperuricemia: from systems pharmacology to mechanistic PK/PD Wednesday 15:15-16:40 |
II-19 Rujia Xie Relationship between the Dose of Urate Lowering Therapies and Serum Uric Acid in Healthy Volunteers and Gout Patients: A Model Based Meta-Analysis (MBMA) Wednesday 15:15-16:40 |
II-34 Mita Thapar Eltrombopag population pharmacokinetics-pharmacodynamics and effect on platelet counts following different regimens in Chinese adult patients with chronic primary immune thrombocytopenia Wednesday 15:15-16:40 |
II-46 Anne van Rongen Population pharmacokinetics of paracetamol and glucuronide, sulphate and CYP2E1 mediated metabolites in morbidly obese patients Wednesday 15:15-16:40 |
II-64 Dan Wright Allopurinol dosing in patients with renal impairment Wednesday 15:15-16:40 |
II-65 Kehua Wu Genome-wide interrogation of FEV1 longitudinal model in asthmatic children Wednesday 15:15-16:40 |
II-68 Hadzliana Zainal Concentration-effect relationship of epidermal growth factor receptor inhibitor for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Wednesday 15:15-16:40 |
II-72 Fan Zhang Application of a mixture model to lamotrigine XR bioequivalence study Wednesday 15:15-16:40 |
II-74 Xuan Zhou A Systems Pharmacology Model for Predicting Anticoagulant Effects of Rivaroxaban in Healthy Subjects: Assessment of Drug Pharmacokinetic and Binding Kinetic Properties Wednesday 15:15-16:40 |
III-07 Helena Edlund Covariate analysis of infliximab in Crohn’s disease using available PK models as prior Thursday 10:20-11:45 |
III-09 Rena Eudy-Byrne Sclerostin-Mediated Osteocyte Control in Bone Remodeling: Extension of a Multiscale Systems Model to Consider New Therapies for Osteoporosis Thursday 10:20-11:45 |
III-13 Linda Franken Pharmacokinetics of morphine, morphine-3-glucuronide and morphine-6-glucuronide in terminally ill patients. Thursday 10:20-11:45 |
III-19 Charkoftaki Georgia Population pharmacokinetics of cyclophosphamide and its 4-OH metabolite in patients with glomerulonephritis Thursday 10:20-11:45 |
III-23 Bojana Golubovic Population pharmacokinetic analysis of tacrolimus TDM data in stable kidney transplant patients Thursday 10:20-11:45 |
III-24 Ignacio Gonzalez-Garcia Development of a Systems Pharmacology Model for Inflammatory Bowel Disease (IBD) Thursday 10:20-11:45 |
III-39 Young-A Heo Modeling of blood pressure lowering effect for co-administration of valsartan and amlodipine Thursday 10:20-11:45 |
III-41 Jules Heuberger Population Pharmacokinetic/Pharmacodynamic Modeling of a next generation recombinant human Factor VIIa (LR769) to Derive the Dose to be Studied in Phase 3. Thursday 10:20-11:45 |
III-64 Evgenia Kartsaki Translating Pharmacogenomics for Personalised Medicine Thursday 10:20-11:45 |
III-73 Brigitte Lacroix A time-to-event model for the immunogenicity of certolizumab pegol in rheumatoid arthritis subjects Thursday 10:20-11:45 |
IV-02 Diao Lei CD25 Occupancy by Daclizumab HYP in Patients with Relapsing Forms of Multiple Sclerosis Thursday 15:20-16:40 |
IV-07 Dominik Lott Population pharmacokinetics of the selective S1P1 receptor modulator ponesimod and its primary metabolites in healthy and organ-impaired subjects Thursday 15:20-16:40 |
IV-21 Johanna Melin Population pharmacokinetic analysis of AZD4818 in healthy volunteers following three different routes of administration. Thursday 15:20-16:40 |
IV-23 Enrica Mezzalana Integrating Target Mediated Drug Disposition (TMDD) into a minimal physiologically based modelling framework: evaluation of different quasi-steady-state approximations Thursday 15:20-16:40 |
IV-30 Morris Muliaditan Determinants of variability in drug exposure and implications for dose selection in tuberculosis patients Thursday 15:20-16:40 |
IV-32 Efthymios Neroutsos Population pharmacokinetic study of Mycophenolic acid in patients with renal disease Thursday 15:20-16:40 |
IV-46 Gab-jin Park Drug-Drug Interaction Analysis of a Drug with Long Elimination Half-life Using Population Pharmacokinetic Approach Thursday 15:20-16:40 |
IV-69 Dirk Garmann RTTE analysis of repeated bleeding events in haemophilia A after recombinant factor VIII treatment Thursday 15:20-16:40 |
IV-70 Leire Ruiz Cerdá Systems Pharmacology Model of the Co-stimulation Process of Immune Response in Systemic Lupus Erythematosus. Thursday 15:20-16:40 |